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ABSTRACT 
The present research work involved synthesis of some new 
pyridazine derivatives and evaluation of their analgesic and anti-
inflammatory activities in experimental animals to obtain safer 
non-steroidal anti-inflammatory agents (NSAIDs). Friedel-Crafts 
acylation reaction of succinic anhydride with toluene in the 
presence of anhydrous aluminum chloride gave 4-(4-
methylphenyl)-4-oxo-butanoic acid (1). The aryl propionic acid 1 
on reaction with phenyl hydrazine and hydrazine hydrate yielded 
the pyridazinone derivative 2 and 3, respectively. Reaction of the 
compound 3 with phosphorus oxychloride (POCl3) produced the 
corresponding chloropyridazine derivative 4. A 4-hydroxymethyl 
derivative of dihydropyridazinone (5) was synthesized by 
condensing 3 with methanol and formaldehyde (HCHO). The 
compound 5 on further treatment with guanidine hydrochloride in 
ethanol gave the pyridazino-triazine (6). The synthesized 
compounds were investigated for their analgesic activity in mice 
and anti-inflammatory activity in Wistar albino rats. The 
molecular, pharmacokinetic and toxicity properties of the 
synthesized compounds were calculated by Molinspiration and 
Osiris property explorer software. The results of in-vivo anti-
inflammatory studies revealed that the compound. 4 showed 
maximum inhibition in paw edema volume followed by compound 
3 while the compound 4 exhibited excellent  peripheral analgesic 
activity (74%) followed by the compound 5. Compound s 4 and 
5 also showed good central analgesic effect increased the 
reaction time to 90 minutes. All the title compounds except 
compound 5 are predicted to be safe by Osiris online software 
and are likely to have good oral bioavailability as they obey 
Lipinski’s rule of five for drug likeness. 
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INTRODUCTION 
Non-steroidal anti-inflammatory drugs 
(NSAIDs) are the most commonly prescribed 
medications for the treatment and/or 
management of pain, fever, and inflammation. 
However, their long term use is associated with 
gastroenteropathy such as gastric irritation, 
ulceration, bleeding and renal toxicity that limit 
their therapeutic usefulness (Abouzid, et al., 
2012).  Therefore, the synthesis of new 
compounds devoid of such side effects poses a 
challenging task for medicinal chemists. In 
recent years, synthesis of novel pyridazinone 
derivatives and investigation of their chemical 
and biological behavior have gained more 
importance due to their biological, medicinal, 
and agricultural reason. This privileged 
structure attracts the interest of medicinal 
chemists as a nucleus of potential therapeutic 
utility and exhibits several pharmacological 
activities such as analgesic (Asif, et al., 2011), 
anti-inflammatory (Gokce, et al., 2009), 
antidepressant (Coelho, et al., 2003), 
antihypertensive (Demirayak, et al., 2004), 
anticonvulsant (Rubat, et al., 1990), cardiotonic 
(Amin, et al., 2010), diuretic (Akahane, et al., 
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1999), and anti-HIV (Livermone, et al., 1993) 
activities. Certain pyridazinone derivatives 
containing the 2-phenyl-indolyl moiety have 
also shown anti-cancer activity (Murty, et al., 
2012). In addition, pyridazinones act as core 
nucleus in various drugs e.g. Sulmazole, 
Levosimendan, Amipizone, Indolidan, 
Imazodan, Pimobendan, Emorfazone, 
Zardaverine, Milrinone (Alam, et al., 2014). The 
easy functionalization at various ring positions 
makes them an attractive synthetic building 
block for designing, synthesis and discovery of 
new drugs. The incorporation of this versatile 
biologically accepted pharmacophore in 
established medicinally active molecules results 
in wide range of pharmacological effects.  
The currently used anti-inflammatory 
and analgesic compounds inhibit the synthesis 
of non selective or selective cyclooxygenases 
(COX1 & COX2) or prostaglandin, histamine 
and bradykinin (Sahina, et al., 2004; Dogruer, et 
al., 2003; Tazkoparan et al., 2000). It has been 
suggested that prostaglandins and bradykinins 
play a major role in the analgesia or pain. So it 
may be predicted that the title compounds may 
act by inhibiting the synthesis of these chemical 
mediators involved in causing pain as well as 
inflammation (Raskin, 1999; McCarthy, 1998).  
The pyridazinones having characteristic 
pharmacological features, relative stability and 
ease of preparation contemplated us to 
synthesize some new derivatives of 
pyridazinones following molecular docking 
studies with a view to explore their potency as 
good analgesic and anti-inflammatory agents. 
Since it is impossible to synthesize all the 
possible compounds and to test all the available 
ones so molecular modeling makes this 
approach easier and limits to some fixed 
number of compounds (Regina, et al., 2008).  
The compounds which were found to possess 
high Mol Dock Score and formed maximum 
number of H-Bond interaction with the 
receptors were synthesized in the laboratory 
and evaluated for their anti-inflammatory and 
analgesic activities. 
 
MATERIAL AND METHODS 
Chemistry 
Chemicals and solvents were purchased 
from Sigma Aldrich and Merck for the 
synthesis of title compounds. All chemical 
reactions were monitored by thin layer 
chromatography (TLC) on glass plates coated 
with silica gel using solvent system Toluene: 
Ethyl Acetate: Formic acid (5:4:1). Melting 
points were determined on glass slides using 
Labindia MR-VIS visual melting range 
apparatus. Infrared spectra were recorded on 
Hitachi spectrophotometer and proton nuclear 
magnetic resonance was recorded on Bruker’s 
300Hz instrument with DMSO as solvent and 
TMS as an internal reference standard. 
Chemical shifts are reported in ä (parts per 
million values). Mass spectra were scanned on 
Brukers micrOTOF-QII, ESI Mass 
spectrophotometer. 
 
Synthesis of compounds (2-6) 
4-(4-Methylphenyl)-4-oxobutanoic acid (1)  
It was synthesized as per the reported 
method (Asif et al., 2011). Yield 45%, m.p. 104-
105ºC, Rf 0.86, IR (KBr, cm-1): ímax 1582, 1682 
(C=O), 3433 (OH). 1H NMR (DMSO-d6, 
ppm): ä 2.32 (s, 3H, CH3), 2.68 (t, 2H, CH2), 
3.25 (t, 2H, CH2), 7.03-7.06 (d, 1H, Ar), 7.66-
7.68 (d, 1H, Ar), 7.86-7.88 (d, 1H, Ar), 8.09-
8.11 (d, 1H, Ar), 11.95 (s, 1H, COOH). 13C 
NMR (DMSO-d6, ppm): ä 133.8 (C of C1), 
200.1 (C of C2), 34.2 (CH2 of C3), 30.7 (CH3 of 
C4), 177.3 (C of C5). EI-MS (m/z): 192 [M+] 
C11H12O3. 
 
6-(4-Methylphenyl)-2-phenylpyridazin-3(2H) 
-one (2)  
Required amount of phenyl hydrazine 
(2.14mmol) was added to a stirred and refluxing 
solution of compound 1 (2.13mmol) in 
aldehyde free ethanol (40mL). The reaction 
mixture was refluxed for 8h under continuous 
stirring. The reaction mixture was concentrated 
to half the volume and left overnight in 
refrigerator for crystallization. Yield 29.3%, 
m.p. 306oC, Rf 0.51, IR (KBr, cm-1): ímax 1350, 
1450, 1589 (Ar, str), 1674 (-C=N), 1713 
(C=O), 3387 (Ar-H str). 1H NMR (DMSO-d6, 
ppm): ä 1.64-1.72 (t, 2H, CH2), 1.99-2.38 (t, 2H, 
CH2), 2.23 (s, 3H, CH3), 7.11-7.14 (d, 1H, Ar), 
7.31-7.34 (m, 3H, Ar), 7.42-7.48 (m, 3H, Ar), 
7.88-7.93 (d, 1H, Ar), 7.96-8.05 (d, 1H, Ar). 13C 
NMR (DMSO-d6  ppm): ä 140.7 (C of C-1), 
129.2 (CH of C-2, C-6), 129.1 (CH of C-3, C-
5), 131 (C of C-4), 145.3 (C of C-7),  24.5 (CH2 
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of C-8), 32.5(CH2 of C-9), 173 (C of C-10). EI-
MS (m/z): 264 [M+] C17H16N2O. 
 
6-(4-Methylphenyl)-4,5-dihydropyridazin-
3(2H)-one (3) 
Required amount of hydrazine hydrate 
(2.14mmol) was added to a stirred and refluxing 
solution of compound 1 (2.13mmol) in 
aldehyde free ethanol (40mL). The reaction 
mixture was refluxed for 5-6h under 
continuous stirring. The reaction mixture was 
concentrated to half the volume and left 
overnight in refrigerator for crystallization. 
Yield 30.7 %, m.p. 224-226ºC, Rf 0.49, IR (KBr, 
cm-1): ímax 1643 (-C=N), 1674 (C=O), 3364 (-
N-H). 1H NMR (DMSO-d6, ppm): ä 1.63-
1.71(t,   2H, CH2), 1.89-2.33 (t, 2H, CH2), 2.19 
(s, 3H, CH3), 7.10-7.14 (d, 1H, Ar), 7.34-7.37 
(d, 1H, Ar), 7.42-7.46 (d, 1H, Ar), 7.77-7.91 (d, 
1H, Ar), 9.20 (bs, 1H, NH). 13C NMR (DMSO-
d6, ppm): ä 140.7 (C of C-1), 129.2 (C-H of C-
2,C-6), 129.1 (C-H of C-3), 131 (C of C-4), 
146.6 (C of C-7), 24.2 (CH2 of C-8), 35.1 (CH2 
of C-9). EI-MS (m/z): 188 [M+] C11H12N2O. 
 
3-Chloro-6-(4-methylphenyl)-pyridazine (4)  
 A mixture of compound 3 and POCl3 
(10 mL) was refluxed for 5h, cooled and treated 
with crushed ice. The solid so obtained was 
filtered off and crystallized from petroleum 
ether (b.p.80-100ºC). Yield 20%, m.p. 222-
224ºC, Rf 0.78, IR (KBr, cm-1): ímax, 1342, 1445, 
1579 (Ar, str), 1710 (C=O). 1H NMR (DMSO-
d6, ppm): ä 1.59-1.70 (t, 2H, CH2), 1.89-2.17 (t, 
2H, CH2), 2.20 (s, 3H, CH3), 7.11-7.14 (d, 1H, 
Ar), 7.31-7.34 (d, 1H, Ar), 7.42-7.46 (d, 1H, 
Ar), 7.77-7.91 (d, 1H, Ar). 13C NMR (DMSO-
d6, ppm): ä 129.2 (CH of C1), 129.1 (CH of C2), 
140.7 (C of C6), 131 (C of C7), 24.3 (CH3 of C6). 
EI-MS (m/z): 206 [M+] C11H11ClN2. 
 
2-(Hydroxymethyl)-6-(4-methylphenyl)-4,5-
dihydropyridazin-3(2H)-one (5)  
To a solution of compound 4 (0.001mol) 
in methanol (30mL), formaldehyde (37-41% 
aqueous solution) (2.5mL) was added and the 
mixture was refluxed for 9.5h. After 
completion of the reaction, methanol was 
distilled off and the residue was poured into 
crushed ice to separate out the product, (5). It 
was filtered and crystallized from methanol. 
Yield: 24%, m.p. 227-229oC, Rf 0.81, IR (KBr, 
cm-1): ímax 1677 (C=N), 1680 (C=O), 3411-3421 
(b, OH). 1H NMR (DMSO-d6, ppm): ä 1.61-
1.68 (t, 2H, CH2), 2.02-2.28 (t, 2H, CH2), 2.35 
(s, 3H, CH3), 4.02 (s, 1H, OH), 5.44 (s, 2H, 
CH2), 7.14-7.18 (d, 1H, Ar), 7.28-7.33 (d, 1H, 
Ar), 7.55-7.63 (d, 1H, Ar), 7.72-7.84 (d, 1H, 
Ar). 13C NMR (DMSO-d6, ppm): ä 129.2 (CH2 
of C1), 129.1 (CH2 of C2), 140.7 (CH of C5), 
146.6 (CH of C6), 162.2 (C of C9). EI-MS 
(m/z): 218 [M+] C12H14N2O2. 
 
Preparation of compound 7-(4-
methylphenyl)-3,4,8,9-tetrahydro-2H-
pyridazino[1,6-á][1,3,5]triazin-2-imine (6) 
A mixture of compound 5 (0.001mol) 
and guanidine hydrochloride (0.001mol) was 
heated in an oil bath for 30 min, cooled and 
triturated with ethanol. The whole content was 
refluxed on a water bath for 8h. After 
completion of the reaction, ethanol was 
distilled off and the residue was poured into 
crushed ice to separate out the compound 6. 
The separated solid was filtered and crystallized 
from ethanol.  Yield: 30%, m.p. 185 oC, Rf 0.69, 
IR (KBr, cm-1): ímax 1549 (N-H), 1681 (C=N), 
2923 (C-H). 1H NMR (CDCl3 ppm): ä 1.64-1.72 
(t, 2H, CH2), 2.40 (s, 3H, CH3), 2.53-2.79 (t, 
2H, CH2), 5.92 (s, 2H, CH2), 7.16-7.22 (d, 1H, 
Ar), 7.29-7.35 (d, 1H, Ar), 7.53-7.61 (d, 1H, 
Ar), 7.80-7.92 (d, 1H, Ar), 8.50 (s, 1H, NH). 13C 
NMR (CDCl3, ppm): ä 128.7(CH2 of C1), 
129.3(CH2 of C2), 140.7(CH of C6), 164(CH of 
C7), 23.6(CH2 of C11), 20.1(CH2 of C12). EI-MS 
(m/z): 241 [M+] C13H15N5. 
 
In vivo pharmacological activity 
Experimental animals  
Male Swiss albino mice weighing 25-30g 
and Wistar albino rats weighing 180-250g were 
used for the evaluation of anti-inflammatory 
and analgesic activities. A prior approval for the 
study was obtained from Kurukshetra 
University animals ethics committee (Reg No. 
562/GO/02/a/CPCSEA). The animals were 
fed ad libitum with standard laboratory rodent’s 
chow and free access to drinking water. 
Animals were housed in polypropylene cages (5 
per cage) with dust free rice husk as a bedding 
material under laboratory condition with 
controlled environment of temperature 25 ± 
2°C and 12h Light/dark cycle as per CPCSEA 
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guidelines. The animals were given a week time 
to get acclimatized with laboratory conditions.  
 
Determination of anti-inflammatory activity 
 The anti-inflammatory activity of 
synthesized compounds was determined using 
carrageenan induced rat paw edema as per the 
reported method (Winter, et al., 1962). Rats 
were weighed, marked/numbered and divided 
in to seven groups having five animals in each. 
Group 1 was used for control (10mg/Kg), 
Group 2 for standard (Indomethacin 
10mg/Kg) and Group 3-7 for test drugs 
(10mg/Kg). A mark was made on the left hind 
paw near tibio-tarsus junction so that every 
time the paw was dipped in the 0.5% NaCl 
solution column up to the fixed mark to ensure 
measurement of constant paw volume. Initial 
paw volume of all the animals was recorded. 
After 30 min. of administration of test and 
standard drug, carrageenan was injected 
intraperitoneally into the subplantar region of 
left hind paw of all animals. The paw volume 
was measured using a plethysmometer (model 
7140, Ugo Basile, Italy) at 0h (before 
carrageenan injection), 1, 2, 3 and 4h after drug 
treatment (Vogel, 2002).  The anti-inflammatory 
effect of synthesized compounds i.e. percent 
inhibition of inflammation (edema) was 
calculated by the following equation: 
 
% inhibition = 
(Vc-Vt) 
X 100 
Vc 
 
Where Vt is the paw volume in drug treated 
animals and Vc is the paw volume of control 
group of animals. 
 
Determination of analgesic activity 
The central and peripheral analgesic activity of 
the title compounds was studied by writhing 
tests and tail immersion method, respectively 
(Collier, et al.,, 1968; Seigmund, et al., 1957).  
 
Writhing test  
Swiss albino mice of either sex weighing 
between 20-25g were used in the study. Acetic 
acid in a concentration of 1% v/v and 
10mL/kg/ i.p. was administered to induce 
writhing. Seven groups having five animals in 
each were used for the study. Group 1 served 
as control (10mL/Kg), Group 2 received 
standard drug (Indomethacin 10mg/kg) and 
Group 3-7 were administered test compounds 
(10 mg/Kg). Group I was administered acetic 
acid solution alone and served as negative 
control. The test and standard groups of 
animals (groups 2-7) were administered the test 
compounds and the standard drug 30 min prior 
to acetic acid administration respectively. The 
mice were then observed for ten minutes and 
the numbers of writhing for each animal were 
recorded during that time period. For scoring 
purposes, writhing was indicated by stretching 
of the abdomen with simultaneously stretching 
of at least one hind limb.  
 
Tail immersion method 
Mice were held in position in a suitable 
restrainer with the tail protruding out. The tail 
up to 5 cm was dipped in a beaker of water at 
55°C. All the dose of standard and test drugs 
(10mg/kg body weight) was prepared in 0.5% 
w/v Tween-80 which served as drug vehicle 
and administered orally. Indomethacin, (10mg 
/kg body weight i.e. 28g) was used as a 
reference drug for comparison purpose.               
The time taken by the mice to withdraw the  
tail clearly out of water was recorded as  the 
reaction time. The reaction time was       
measured after 30, 60, 90, and 120min, 
respectively. 
 
Calculation of pharmacokinetic 
parameters and toxicity potential 
Molecular properties were calculated by 
using online Molinspiration software version 
2011.06 (www.molinspiration.com) to evaluate 
the oral bioavailability and drug likeness of the 
synthesized compounds (Lipinski, et al., 1997). 
The calculated properties were also compared 
with the reference drugs, indomethacin.  
Pharmacokinetic parameters such as 
toxicity potential, solubility and overall drug-
likeness of pyridazine compounds were 
predicted by using Osiris property explorer 
(www.organicchemistry.org/prog/peo/). The 
results of computer aided screening are valued 
and color coded green, yellow or red for 
properties such as effect on reproductive 
system, irritant effect, mutagenicity and 
tumorigenicity. High toxicity risks are shown in 
red color, while green color indicates a drug-
conform behavior, and safety in vivo. 
Synthesis, Computer Aided Screening  
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Statistical analysis 
The statistical analysis was performed 
using GRAPHPAD INSTAT 3 software 
(Graph Pad Software Inc., San Diego, CA). 
Data obtained from animal experiments were 
expressed as arithmetic mean ±SEM. The 
comparison between various groups was 
performed by one-way analysis of variance 
(ANOVA) where p<0.05 was considered to be 
statistically significant (*p<0.01, **p<0.05 
compared to control). 
 
RESULT AND DISCUSSION 
Chemistry 
Pyridazine is an important heterocyclic 
scaffold for designing medicinal agents with 
varying biological actions. Pyridazinone, being 
an easy target for functionalization at various 
ring positions, makes it an interesting and 
attractive pharmacophore for the development 
of new and potent agents in anti-inflammatory 
therapy. A large number of substituted 
pyridazinone derivatives possessing analgesic 
activity along with other useful pharmacological 
properties have been reported (Gokce, et al., 
2009). Emorfazone (4-ethoxy-2-methyl-5-
morpholino-3(2H)-pyridazinone) is a pyrida-
zinone derivative which is currently used 
clinically in the management of pain and 
inflammation. Piaz et al., in 1996 reported the 
synthesis and antinociceptive activity of 4-
amino-2-methyl-6-phenyl-5-vinyl-3(2H)-pyrida-
zinone which was found to be many fold 
potent than the emorfazone (Piaz, et al., 1996). 
Prompted by these findings, a novel series of 
2/3-substituted-6(4-methylphenyl)-4,5-dihydro-
pyridazin3(2H)-ones and Pyridazine substituted 
Triazine have been synthesized. Synthetic 
routes were developed that allow efficient 
preparation of analogues with varied 
substitutions on the pyridazinone ring. 
In the present study various compounds 
incorporating a 3(2H)-pyridazinone ring were 
synthesized as outlined in Scheme I. Friedel-
Crafts acylation reaction of succinic anhydride 
with toluene in the presence of anhydrous 
aluminum chloride, gave 4-(4-methylphenyl)-4-
oxo-butanoic acid (aryl propionic acid) 1. The 
acid 1 with hydrazine derivatives produced the 
Pyridazinone derivative 2 and 3. Reaction of 
the compound 3 with phosphorus oxychloride 
(POCl3) gave the chloropyridazine derivative 4. 
Reaction of the 3 with methanol (CH3OH) and 
formaldehyde (HCHO) resulted in formation 
of 4-hydroxymethyl derivative of dihydro-
pyridazinone 5. The compound 5 on reaction 
with guanidine hydrochloride and ethanol 
yielded the compound 6. Purity of compounds 
was checked by a single-spot TLC in solvent 
system toluene: ethyl acetate: formic acid 
(5:4:1). The spots on TLC were located          
under iodine vapors/UV light. Compounds 
were characterized on the basis of spectral data 
(IR, 1H NMR, 13C NMR and Mass 
spectrometry). 
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Scheme I: Synthesis of 2/3-substituted-6(4-
methylphenyl)-4,5-dihydropyridazin3(2H)-ones 
and Pyridazine substituted Triazine 
 
Spectral data of all the newly synthesized 
compounds were in full agreement with the 
proposed structures. In general, Infra Red 
spectra (IR) of title compounds showed 
presence of functional groups viz. C=N, C=O, 
N-H, O-H, at 1643-1677, 1674-1713, 3364, 
3411-3421, cm-1, respectively. The 1H NMR 
spectra of the compounds exhibited the            
signal in the form of a singlet near ä 2.19-2.40 
for tolyl CH3 protons. The two methylene 
protons (-CH2) in pyridazine ring appeared as 
triplet in the region ä 1.59-1.72 and ä 1.89- 2.79.  
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An additional singlet of two protons at ä 5.92 in 
the spectrum of compound 6 was ascribed to –
CH2 group of triazine ring. Compound 3 and 
compound 6 showed a broad singlet at ä 8.5-9.2 
due to NH protons. Aromatic protons were 
observed in the region ranging from ä 7.11-
8.05. The 13C NMR spectrum showed the 
signal with ä 140.7 at C-1, ä 129.2 at C-2, C-6, ä 
129.1 at C-3, C-5, ä 131 at C-4, ä 145.3 at C-7, ä 
24.5 at C-8, ä 32.5 at C-9, ä 173 at C-10. The 
molecular ion peak (M+) for all the synthesized 
compounds was also obtained in mass spectra 
and was of good intensity. 
 
Pharmacological evaluation 
Anti-inflammatory activity 
The synthesized compounds were 
screened for in- vivo anti-inflammatory activity 
by a commonly used experimental animal 
method of carrageenan induced rat paw edema 
(Winter, et al., 1962). The edema induced by 
carrageenan involves release of various 
inflammatory mediators mainly prostaglandins, 
bradykinins and other related autocoids which 
cause migration of macrophages and 
polymorphonuclear neutrophils to the site of 
inflammation (Fernandes, et al., 2007). The 
effect of tested compounds on % inhibition of 
edema was measured after 30, 60, 90 and 120 
min and the results are presented in table I. A 
gradual increase in paw volume with time was 
observed in control group. Administration of 
standard and test compounds significantly 
reduced the paw volume after 120 min and thus 
showed anti-inflammatory activity. The % 
inhibition of rat paw volume due to the 
screened compounds at 30, 60, 90 and 120min 
time interval ranged 10-15%, 24-44%, 33-45% 
and 29-47%, respectively. Compounds, 3 and 4, 
had smaller paw volume than the positive 
control and were found to be more potent. All 
the tested compounds except compound 5 
exhibited the maximum reduction in paw 
volume at 120 min while 5 displayed the 
maximum protection at 90 min. It could be 
concluded that the anti-inflammatory activity of 
the synthesized compounds could be due to the 
inhibition of inflammatory mediators release 
and possibly due to the inhibition of 
cyclooxyenase synthesis similar to 
indomethacin. It was observed that substitution 
of 2-phenyl ring at  p- position with –CH2OH 
in compound 5, decreases the anti-
inflammatory activity. However, the best 
activity is shown by compound 6-(4-
methylphenyl)-4,5-dihydropyridazin-3(2H)-one (3) 
having no substituent at 2nd position of 
pyridazine ring. Further, replacing an oxo 
group at 3rd position with a –chloro group does 
not lead to change in the activity. 
 
Analgesic activity by acetic acid induced 
writhing method 
The synthesized compounds were 
screened for analgesic activity by Acetic-acid 
induced writhing method. It is a sensitive 
screening method used to assess peripheral 
analgesic activity (Hunskaar and Hole, 1987). 
Standard drug indomethacin inhibited the 
acetic induced writhing by 76.3% while test 
compounds also showed good peripheral 
analgesic activity (59-74%) comparable to 
Table 1: Effect of compounds on carrageenan induced Paw edema volume in rats. 
 
S. 
No 
Treatment Paw edema volume Mean±SEM (% inhibition) 
30 min. 60 min 90 min. 120 min. 
 1 Control 0.4±0.02 0.7±0.02 0.7±0.0* 0.9±0.01* 
 2 Standard(a) 0.3±0.02(10%) 0.4±0.02*(36%) 0.5±0.0*(36%) 0.5±0.0 (46%) 
 3 2                    0.5±0.01(17%) 0.4±0.05*(33%) 0.5±0.0*(36%) 0.5±0.02*(43%) 
 4 3 0.3±0.02(15%) 0.3±0.01*(44%) 0.4±0.08*(45%) 0. 5±0.03*(47%) 
 5 4 0.3±0.02(13%) 0.3±0.01*(44%) 0.4±0.08*(45%) 0. 5±0.03*(47%) 
 6 5 0.3±0.03(12%) 0.5±0.02*(30%) 0.5±0.01*(35%) 0. 7±0.01*(29%) 
 7 6 0.5±0.02(15%) 0.5±0.03*(24%) 0.5±0.0*(33%) 0. 6±0.02*(39%) 
 
Values are expressed as mean ±SEM (N=5); a – Indomethacin (10 mg/kg, i.p.) used as a standard drug; 
*p<0.01 compared with vehicle control, **p<0.05 compared with vehicle control (ANOVA). 
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standard. In general the peripheral analgesic 
activity increased with time. Compound 3-
chloro-6-(4-methylphenyl)-pyridazine (4) was found 
to be the most potent analgesic agent with a % 
inhibition value of 74%. The results of 
analgesic activity are shown in table II.  
 
Analgesic activity of compounds by tail 
immersion method 
The effect of synthesized compounds on 
central analgesic activity was investigated by tail 
immersion method and the results are 
presented in table III. As it can be seen from 
table III, that after the administration of test 
compounds, reaction time (analgesic activity) 
gradually increased with time and the peak 
analgesic activity was observed at 90 min, after 
which analgesia starts to regress.  Compound 4  
showed comparable activity with respect to 
standard drug. Other compounds also showed 
moderate to good analgesic activity.  
Pharmacokinetic parameters and 
toxicity potential  
Lipinski’s rule is commonly used in drug 
design to predict fate of drug in vivo. A 
compound that obeys follows Lipinski’s rule of 
five is expected to be absorbed orally (Lipinski, 
et al., 1997).  To obey Lipinski’s rule, a molecule 
should have a) molecular weight <500, b) log 
P<5, c) number of hydrogen bond donors (OH 
and NH groups) ≤5  and d) ≤10 hydrogen 
bond acceptors (notably N and O). Molecular 
properties including Log P, TPSA, number of 
hydrogen bond donor and acceptor, molecular 
weight etc were calculated with the help of 
Molinspiration online to evaluate the drug 
likeness of synthesized compounds as per the 
Lipinski’s rule of five in search of the lead 
NSAID candidate(s). It can be seen from the 
results presented in the table 4 that all the 
synthesized pyridazine derivatives are likely to 
be absorbed orally as they did not show any 
Table II.   Effect of compounds on Acetic-acid induced writhing in mice. 
 
S. 
No. 
Treatment Dose (mg/kg) 
Number of Writhes 
Mean ± SEM 
% inhibition 
1 Control    -------   39.6 ± 2.1** -------- 
2 Standard (a)     50 9.4 ± 0.5** 76.3% 
3  2     50 16.2 ± 0.7* 59% 
4  3     50 14.6 ± 1.7** 64.5% 
5  4     50 10.0 ± 0.9** 74% 
6  5     50 12.8 ± 1.0** 67.6% 
7  6     50 14.6 ± 1.7* 63% 
 
Values are expressed as mean ±SEM (N=5); a – Indomethacin (10 mg/kg, i.p.) used as standard drug in 
Acetic-acid induced writhing; *p<0.01 compared with vehicle control, **p<0.05 compared with vehicle 
control (ANOVA).  
 
Table III.  Effect of compounds on Tail immersion method.  
 
S. No. Treatment Dose (mg/kg) 
After Dose Reactiontime (insec.) Mean ± SEM 
30 min. 60 min 90 min. 120 min. 
1. Control ------- 2.6±0.2* 2.6±0.2* 2.6±0.2* 2.4±0.2* 
2. Standard (a) 50 5.6±0.2* 7.8±0.5* 8.8±0.3* 8.2±0.3* 
3.  2 50 4.6±0.4* 5.6±0.4* 7.0±0.3* 5.6±0.2* 
4.  3 50 3.8±0.3 3.6±0.2 5.2±0.3* 4.4±0.2* 
5.  4 50 5.4±0.2* 6.6±0.4* 8.4±0.4* 6.6±0.2* 
6.  5 50 5.6±0.2 6.2±0.4** 7.2±0.5* 7.2±0.5* 
7.  6 50 5.6±0.2* 5.6±0.2* 6.8±0.3* 6.8±0.3* 
 
Values are expressed as mean ±SEM (N= ); a – Indomethacin (10 mg/kg, i.p.) used as standard drug in Tail 
immersion method; *p<0.01 compared with vehicle control, **p<0.05 compared with vehicle control 
(ANOVA).  
Sukhbir Lal Khokra 
Volume 26 Issue 4 (2015)  207 
violation of Lipinski’s rule of five.  Also the 
chemical descriptors to predict pharmaco-
kinetic properties of compounds 2-6 are similar 
to the standard drug indomethacin. 
Results of overall drug score and toxicity 
profile of title compounds 2-6 by Osiris 
property explorer are tabulated in table V. This 
online program predicts on the basis of 
functional group similarity of the investigated 
compound with the extensively in-vitro and in-
vivo studied compounds present in its data base. 
Green color suggests low toxic tendency, 
yellow shows the mild toxicity and red color 
indicates high probability of toxicity. It is very 
obvious from the presented data that except 
compound 5, all other compounds are 
predicted to be safe and expected to show low 
or no toxicity regarding mutagenicity, 
tumorigenicity, irritant effect and effect on 
reproductive system. The probability of 
developing the molecule in to a drug molecule 
was predicted on the basis of drug score which 
ranged from 0.14-0.87. However, the high drug 
score was obtained for compounds 3 and 6 
(0.87 and 0.83) while 2 and 4 had the moderate 
drug score (0.71 and 0.54). The drug score of 
compound 4 (0.54) was at par with the drug 
score of indomethacin (0.56) but compounds 2, 
3 and 6 exhibited better score than the 
reference compound. It was interesting to note 
that compound 5 had the lowest drug score of 
0.14 vis a vis it was predicted to be highly toxic 
with regards to tumorigenicity, irritant effect 
and  reproductive system Solubility of 
pyridazine derivatives was also predicted to be 
within the permissible optimum range.  
 
CONCLUSION 
In the present study, some novel 
pyridazinone derivatives were designed, 
synthesized, characterized and evaluated for 
their in-vivo analgesic and anti-inflammatory 
activities. The results of the pharmacological 
screening indicated that pyridazine derivatives 
possess significant analgesic activity associated 
with NSAIDs properties. All title compounds 
exhibited anti-inflammatory activity (Table I) 
that lasted for 90min and the potency increased 
Table IV. Drug likeness score of synthesized compounds by molinspiration software. 
 
Compound miLog Pa TPSAb 
n 
Atoms 
n 
ONc 
n 
OHNHd  
n 
violation 
n 
rotbe 
MWf 
2 3.7 32.7 20 3 0 0 2 264.3 
3 1.8 41.5 14 3 1 0 1 188.2 
4 3.2 24.7 14 2 0 0 1 206.7 
5 1.4 52.9 16 4 1 0 2 218.3 
6 1.9 63.8 18 5 2 0 1 241.3 
Indomethacin 4.0 68.5 25 5 1 0 4 357.8 
 
aLogarithm of partition coefficient between n-octanol and water (miLog P); btopological polar surface area 
(TPSA); cnumber of hydrogen bond acceptors  (n-ON); dnumber of hydrogen bond donors (n-OHNH);  
enumber of rotatable bonds (n-rotb);); fmolecular weight (MW). 
 
Table V.  Drug-likeness/scores and toxicity calculations of pyridazine derivatives (2-6) based on 
Osiris property explorer. 
 
Compound Solubility 
Drug-
likeness 
Drug 
score 
Mutagenic  Tumorigenic  Irritant 
Reproductive 
effect 
2 -4.1 2.4 0.71 Green Green Green Green 
3 -3.3 1.9 0.83 Green Green Green Green 
4 -3.5 -0.7 0.54 Green Green Green Green 
5 -3.2 1.6 0.14 Yellow Red Red Red 
6 -3.2 2.8 0.87 Green Green Green Green 
Indomethacin  -5.4 9.4 0.56 Green Green Green Green 
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with time. Among the synthesized 
pyridazinones, compound 4, 3-chloro-6-(4-
methylphenyl)-pyridazine emerged as lead 
compound with good analgesic and anti-
inflammatory activities at par with the reference 
drug. Most of the compounds exhibited 
analgesic effect by both peripheral and central 
mechanisms. The study confirmed the anti-
inflammatory and analgesic potential of 2/3 
substituted pyridazine derivatives. However, 
further detailed investigations are needed to 
establish the safety, efficacy and mechanism of 
this promising class of heterocyclic 
compounds.  
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